Multiple noncoding exons 1 of nuclear receptors NR4A family (nerve growth factor-induced clone B, Nur-related factor 1 and neuron-derived orphan receptor 1) and NR5A1 (steroidogenic factor 1) in human cardiovascular and adrenal tissues by Demura Masashi et al.
Multiple noncoding exons 1 of nuclear
receptors NR4A family (nerve growth
factor-induced clone B, Nur-related factor 1
and neuron-derived orphan receptor 1) and
NR5A1 (steroidogenic factor 1) in human
cardiovascular and adrenal tissues
著者 Demura Masashi, Wang Fen, Yoneda Takashi,
Karashima Shigehiro, Mori Shunsuke, Oe
Masashi, Kometani Mitsuhiro, Sawamura
Toshitaka, Cheng Yuan, Maeda Yuji, Namiki
Mikio, Ino Hidekazu, Fujino Noboru, Uchiyama
Katsuharu, Tsubokawa Toshinari, Yamagishi
Masakazu, Nakamura Yasuhiro, Ono Katsuhiko,
Sasano Hironobu, Demura Yoshiki, Takeda
Yoshiyu
journal or
publication title
Journal of Hypertension
volume 29
number 6
page range 1185-1195
year 2011-06-01
URL http://hdl.handle.net/2297/27783
doi: 10.1097/HJH.0b013e32834626bb
1 
 
 
Multiple noncoding exons 1 of nuclear receptors NR4A family (NGFIB,NURR1,NOR1) and 
NR5A1 (SF1) in human cardiovascular and adrenal tissues 
 
Masashi DEMURAa, Fen WANGa, Takashi YONEDAa, Shigehiro KARASHIMAa, Shunsuke 
MORIa, Masashi OEa, Mitsuhiro KOMETANIa, Toshitaka SAWAMURAa, Yuan CHENGa, Yuji 
MAEDAb, Mikio NAMIKIb, Hidekazu INOc, Noboru FUJINOc, Katsuharu UCHIYAMAc, 
Toshinari TSUBOKAWAc, Masakazu YAMAGISHIc , Yasuhiro NAKAMURAd, Katsuhiko 
ONOd, Hironobu SASANOd, Yoshiki DEMURAe and Yoshiyu TAKEDAa. 
 
a Division of Endocrinology and Hypertension, Department of Internal Medicine,  
Graduate School of Medical Science, Kanazawa University 
b Department of Urology, Graduate School of Medical Science, Kanazawa University  
c Division of Cardiology, Department of Internal Medicine, Graduate School of Medical Science, 
Kanazawa University 
13-1 Takara-machi, Kanazawa 920-8641, Japan 
d Department of Pathology, Tohoku University School of Medicine  
2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan 
e Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, 920-
8530, Japan 
 
Short title: noncoding exons 1 in nuclear receptors 
Information about previous presentations: NONE 
Grant support: KAKENHI (#21790889) (M.D.) 
Conflicts of interest: NONE 
Corresponding author: Masashi Demura, MD 
2 
 
To whom reprint requests should be addressed:  
Masashi Demura, MD 
Division of Endocrinology and Hypertension, Department of Internal Medicine,  
Kanazawa University Graduate School of Medical Science 
13-1Takara-machi, Kanazawa 920-8641, Japan 
Phone: +81-76-265-2252 
Fax: +81-76-234-4251 
E-mail: m-demura@med.kanazawa-u.ac.jp 
 
Word count (including references , but not tables and legends): 3979 words 
Number of tables: 1 
Number of figures: 6 
Number of supplementary digital content files: NONE 
 
Key terms: noncoding exons; nuclear receptor; CYP11B2; artery; adrenal cortex, aldosterone-
producing adenoma; cardiac muscle.
3 
 
Abstract 
Objective: Nuclear receptors are involved in a wide variety of functions, including 
aldosteronogenesis. Nuclear receptor families NR4A (NGFIB,NURR1,NOR1) and NR2F 
(COUP-TFI,COUP-TFII,NR2F6) activate, whereas NR5A1 (SF1) represses CYP11B2 
(aldosterone synthase) gene transcription. The present study was undertaken to elucidate the 
mechanism of differential regulation of nuclear receptors between cardiovascular and adrenal 
tissues. 
Methods: We collected tissues of artery (n=9), cardiomyopathy (CM) muscle (n=9), heart muscle 
(non-CM) (n=6),adrenal gland (n=9) and aldosterone-producing adenoma (APA) (n=9). 5'-rapid 
amplification of cDNA ends (5'-RACE) identified transcription start sites. Multiplex RT-PCR 
determined use of alternative noncoding exons 1 (ANEs). 
Results: In adrenocortical H295R cells, angiotensin II, KCl or cAMP all stimulated CYP11B2 
transcription and NR4A was up-regulated, whereas NR2F and NR5A1 were down-regulated.  5'-
RACE and RT-PCR revealed 4 ANEs of NGFIB (NR4A1), 3 of NURR1 (NR4A2), 2 of NOR1 
(NR4A3), and 2 of SF1 (NR5A1) in cardiovascular and adrenal tissues. Quantitative multiplex 
RT-PCR showed NR4A and NR5A1 differentially employed multiple ANEs in a tissue-specific 
manner. The use of ANEs of NGFIB and NURR1 was significantly different between APA and 
artery. Changes in use of ANEs of NGFIB and NOR1 were observed between CM and non-CM. 
The NR4A mRNA levels in artery were high compared to cardiac and adrenal tissues, whereas 
the NR5A1 mRNA level in adrenal tissues was extremely high compared to cardiovascular 
tissues. 
Conclusions: NR4A and NR5A1 genes are complex in terms of alternative promoter use. The use 
of ANEs may be associated with the pathophysiology of the heart and adrenal gland. 
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Introduction 
Aldosterone classically plays an important role controlling fluid, electrolyte homeostasis 
and blood pressure. Aldosterone synthase, encoded by the CYP11B2 gene, catalyzes the final step 
from corticosterone to aldosterone. Although a major source of aldosterone production is the 
adrenal cortex, aldosterone production occurs in the extra-adrenal sites (heart, blood vessels, 
brain) via the renin-angiotensin-aldosterone system (RAAS) [1, 2, 3] and aldosterone is now 
considered a major cardiovascular risk hormone.  
Aldosterone contributes to vascular smooth muscle cells hypertrophy [4]. Exogenous 
aldosterone administration to mice increases macrophage oxidative stress and atherosclerotic 
lesion development [5] and an aldosterone synthase inhibitor reduces atherosclerosis and 
inflammation in atherosclerotic apolipoprotein E-deficient mice [6]. Furthermore, 
mineralocorticoid blockade improves resistance artery remodeling in hypertensive patients [7]. 
These observations suggest that aldosterone is associated with atherosclerosis development. 
A number of nuclear receptors families, including NR4A (NGFIB, NURR1, NOR1), 
NR2F (COUP-TFI, II, 2F6), and NR5A1 (SF1) have been reported to play a pivotal role in 
CYP11B2 gene transcription. NR4A and NR2F families function as activators [8, 9, 10, 11] 
whereas NR5A1 acts as a repressor [11, 12, 13, 14].  A recent study showed that differentially 
regulated, alternative promoters were common, and that about 60% of protein-coding genes 
employ two or more alternative promoters [15]. As a typical example, the CYP19 (aromatase) 
gene has 11 alternative promoters used preferentially by different tissues[16]. We previously 
cloned promoter I.8 of the CYP19 gene [17]. The ATG translation initiation site is located 38 bp 
downstream of a common splice acceptor site in coding exon II. The 93 kilobase (kb) 5' flanking 
region of the gene contains a number of „physiological‟ promoters with alternative noncoding 
exons 1 (ANEs) that are controlled in a tissue-specific manner. These ANEs are spliced 
alternatively onto a common splice junction, leading to promoter-specific mRNA species that 
encode the identical aromatase protein.  
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We investigated nuclear receptor genes involved in aldosterone synthesis, focusing on 
differentially used alternative promoters with ANEs. In the present study, we identified a number 
of ANEs in nuclear receptor genes including NR4A family members and NR5A1. All these genes 
preferentially employed distinct ANEs between human cardiovascular and adrenal tissues. 
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Materials and Methods 
Cell culture and human tissues 
Adrenocortical H295R cells were purchased from ATCC (Manassas, VA) and maintained 
in DMEM/F12 medium (Invitrogen, Life Technologies Japan Ltd., Tokyo, Japan) supplemented 
with 2.5% Ultroser G (Life Sciences, Cergy, France), penicillin, streptomycin (Life Technologies), 
and 1% ITS premix (BD Biosciences, Bedford, MA). Human renal artery and adrenal gland were 
obtained directly after total nephrectomy for renal cell carcinoma (renal artery, n=4; adrenal gland, 
n=4). In addition, human aorta and adrenal gland were obtained from autopsy specimens (aorta, 
n=5 ; adrenal gland, n=5). Finally, human artery and adrenal gland with 9 samples each were 
obtained. Ventricular tissue was 9 patients with cardiomyopathy (CM) (hypertrophic 
cardiomyopathy, n=8; dilated cardiomyopathy, n=1) and obtained from 6 autopsy cases without 
heart muscle disease (non-CM). Tumor tissue was also obtained from 9 patients with aldosterone-
producing adenoma (APA). Experimental protocols were approved by the Institutional Review 
Board of Kanazawa University and Tohoku University. The purpose of the study was explained 
to all patients, and written informed consent was obtained from each study participant.  
 
Real-time RT-PCR 
Messenger RNA (1 µg) was reverse-transcribed from total RNA using Superscript III 
(Invitrogen, Life Technologies Japan Ltd., Tokyo, Japan) and random hexamer primers, and was 
quantified using real-time PCR. Real-time PCR using the SYBR Green method was carried out 
with gene-specific primer pairs (Table 1). Real-time PCR for CYP11B2 was carried out using the 
TaqMan Gene Expression Assay (Applied Biosystems, Life Technologies Japan Ltd., Tokyo, 
Japan). PCR amplification was performed in triplicate employing an ABI PRISM 7500 Sequence 
Detection System (Applied Biosystems) according to the manufacturer's instructions. The cDNA 
(2 µl) was added to the PCR mixture in a final volume of 20 µl. Thermal conditions for PCR were 
50 °C for 2 min, 95 °C for 10 min and 40 cycles of 95 °C for 15 sec, 60 °C for 1 min.  
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To estimate the copy number of each RNA investigated, 10-fold serial dilutions of 
appropriate cloned DNA were used as templates to generate standard curves, as we previously 
reported [17, 18, 19]. Briefly, a standard PCR was performed to obtain PCR products of target 
genes. Subsequently, PCR products were cloned using TA cloning. Clones containing PCR 
products were cultured overnight in l ml of LB medium with ampicillin. Plasmid DNA was 
extracted using Qiagen Miniprep Kit (Qiagen, Tokyo, Japan). A 10-fold serial dilution of these 
appropriate cloned DNA samples ranging from 10-18 to 10-23 mol/L was produced using DNAse-
free and RNAse-free water (Qiagen) for the DNA standards for each target. Triplicates of each 
cDNA sample, serially diluted standards and no template controls were added to each real-time 
PCR run. 
 
Western blot 
Proteins were isolated using NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo 
Fisher Scientific, Yokohama, Japan). Proteins in SDS-PAGE gels were electrophoretically 
transferred to PVDF membranes and visualized using the SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Fisher Scientific).  
Samples were incubated with anti-NGFIB (NR4A1) (CBX00289; Cosmo Biolabs Inc., 
Tokyo, Japan), anti-NURR1 (NR4A2) (sc-991; Santa Cruz Biotechnology), anti-NOR1 (NR4A3) 
(PP-H7833-00; Perseus Proteomics Inc., Tokyo, Japan), or anti-SF1 (NR5A1) (a generous gift 
from Dr. Ken-ichiro Morohashi). 
 
Rapid amplification of 5' cDNA ends (5'-RACE) 
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To identify transcription start sites (TSSs), 5'-RACE was performed using the 
CapFishing™ Full-length cDNA Premix Kit (Seegene, Inc., Seoul, Korea). The 5'-RACE was 
individually done using total RNA from H295R cells, artery, cardiac muscle, adrenal cortex and 
APA tissues. Briefly, CapFishing™ adaptor-ligated and double stranded cDNA were synthesized 
using SuperScript™ II (Life Technologies Japan Ltd., Tokyo, Japan). The PCR was performed 
using the 5'-RACE primer (5'-gtc tac cag gca ttc gct tca t-3') and a 3' target-specific antisense 
primer (Table 1). The resulting PCR products were fractionated on a 1% agarose gel. All bands 
within the range 150 to 300 bp were subcloned using pGEM-T Easy vector system (Promega 
Corporation, Madison, WI, USA) and sequenced. The sequencing analysis was performed using 
the ABI PRISM BigDye Terminator cycle sequencing kit (Applied Biosystems). The sequencing 
reactions were performed according to the manufacturer‟s instructions and analyzed on an 
ABI310 DNA Sequencer (Applied Biosystems). 
 
Multiplex RT-PCR for measuring noncoding exon 1 usage  
To characterize alternative noncoding exon usage, we performed multiplex RT-PCR as we 
previously reported [17]. Briefly, we designed several different amplicons (Table 1). The reverse 
primers were located at common coding exons and labeled with 6-FAM dye for NGFIB (NR4A1), 
VIC dye for NURR1 (NR4A2), NED dye for NOR1 (NR4A3), and PET dye for NR5A1 (SF1). 
Forward primers were located at different untranslated exons identified by 5'-RACE or in DBTSS 
(DataBase of Transcriptional Start Sites) (http://dbtss.hgc.jp/) (Table 1). Total RNA was treated 
with TURBO DNase (Applied Biosystems) before synthesizing cDNA. The PCR reaction for 
each gene was carried out as follows: denaturation at 96°C for 5 min, 45 cycles of 96°C for 30 sec, 
60°C for 30 sec and 72°C for 30 sec. After PCR amplification, RT-PCR products were separated 
on an ABI 3100 capillary sequencer with an internal size standard GeneScan-600 LIZ (Applied 
Biosystems) and quantified by GeneScan software (Applied Biosystems).
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Results 
Effect of angiotensin II, KCl, and cAMP on nuclear receptor expression in adrenocortical 
H295R cells 
Adrenocortical H295R cells were treated with 100 nM angiotensin II (Ang. II), 16 mM 
KCl, or 1mM cAMP for 6 hours. All three members of the NR4A family, NGFIB (NR4A1), 
NURR1 (NR4A2) and NOR1 (NR4A3), were upregulated in the presence of Ang. II, KCl or 
cAMP (Fig. 1), whereas NR2F family genes (COUP-TFI, COUP-TFII, NR2F6), and NR5A1 
were downregulated in the presence of Ang. II, KCl or cAMP. Each treatment also upregulated 
transcription of the nuclear receptor target gene CYP11B2 in adrenocortical H295R cells (Fig. 1). 
NR4A and 2F families upregulate [8], whereas NR5A1 downregulates the CYP11B2 gene 
transcription [20], suggesting that NR4A family and NR5A1 were considered important for the 
CYP11B2 induction in H295R cells. These results led us to select NR4A family and NR5A1 for 
further analyses.  
 
Identification of transcription start sites (TSSs) and noncoding exons 1 by means of 5′-
RACE and RT-PCR 
According to a default setting in DBTSS (DataBase of Transcriptional Start Sites; 
http://dbtss.hgc.jp/), we separated alternative promoters using a 500-bp interval between two 
transcription start sites. The 5′-RACE for NGFIB cloned canonical ANE and novel ANE directly 
upstream of the coding exon in H295R cells and artery (Fig. 2a). The novel ANE-specific RT-
PCR product was successfully amplified, confirming that the newly-identified NGFIB ANE was 
transcribed in H295R cells. We also identified a number of candidates for further NGFIB ANE in 
DBTSS. Using RT-PCR, we confirmed 4 different ANEs within 17 kb upstream of the first 
NGFIB coding exon. We designated these ANEs as ANE 1, 2, 3, and 4 serially from 5′ to 3′. The 
ATG translation initiation site was located 3 bp downstream of a common splice acceptor site in 
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coding exon 1. Additionally, we observed two different splicing events of ANE1-derived 
transcripts (Fig. 3a).  
We also cloned novel ANE for NURR1 (Fig. 2b) directly upstream of the first coding 
exon. As with the novel NGFIB ANE, we confirmed that the newly-identified ANE was truly 
transcribed. NURR1 differentially employed 3 promoters with distinct ANEs within 2.5 kb of the 
coding region (Fig. 2b). A common splice site was located in the 124 bp noncoding exon 2 (Fig. 
3b). The ATG translation initiation site was 127 bp downstream of a common splice acceptor site.  
We were not able to clone any full-length mRNA species for NOR1 from the 5′-RACE 
cDNA library. According to bioinformation from NCBI, the 6.2 kb 5' flanking region of the 
NOR1 gene contains 2 different promoters with distinct ANEs. Those canonical promoters 
produce 4 different transcript variants (TVs), encoding different isoforms, from the single NOR1 
gene. TV1 (NM_00698.2) and 2 (NM_173198.1) produce the same isoform a. TV3 
(NM_173200.1) and 4 (NM_173199.1) make isoform b and c, respectively. In terms of promoter 
use, TV1, 2, and 4 are derived from an alternative promoter using ANE1, whereas TV3 uses 
ANE2. Using RT-PCR, we confirmed the expression of both ANE1 and 2-derived transcripts in 
H295R cells. The ATG translation initiation site is located 3 bp downstream of a common splice 
acceptor site in coding exon 1 (Fig. 3c).  
Using the same strategy we determined the ANEs of NR5A1 (Fig. 3d). 5′-RACE 
identified ANE1a in H295Rcells. Additionally, RT-PCR confirmed ANE1b-derived transcripts in 
H295R cells among a number of candidate ANEs from DBTSS. 
All ANEs of the 4 nuclear receptor genes identified in this study were spliced alternatively 
onto a common splice junction, leading to promoter-specific mRNA species that encode an 
identical protein. 
 
Analysis of alternative noncoding exon 1 usage in adrenocortical H295R cells 
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ANE3 was the dominant NGFIB noncoding exon 1 in H295R cells as determined by 
quantitative multiplex RT-PCR (Fig. 4). Compared to basal levels, NGFIB-ANE3 transcription 
was significantly increased in the presence of Ang. II (56.9 ± 0.3% vs 50.0 ± 0.2%, mean ± 
(standard deviation (SD)). NURR1 ANE1a was primarily utilized in H295R cells whereas 
ANE1b usage was extremely low (Fig. 4). Compared to basal levels, NURR1 ANE1a usage was 
significantly increased in the presence of Ang. II (62.5 ± 2.7% vs 58.0 ± 3.4%, mean ± SD). 
ANE2 was the dominant ANE for NOR1 (NR4A3) under basal, Ang. II and KCl-stimulated 
conditions in H295R cells. cAMP stimulation appeared to switch the NOR1 dominant ANE from 
ANE2 to ANE1 (Fig. 4). NR5A1 ANE usage appeared to show no significant change (Fig. 4). 
These observations indicate that different stimuli stimulate ANEs of NR4A family in a different 
manner in H295R cells (Fig. 4), and that cAMP may be one pathway used to differentially 
regulate NOR1. 
 
Analysis of gene expression in human cardiovascular and adrenal tissues 
Arterial gene expression of the NR4A family genes was higher than in other tissues from 
non-CM, CM, adrenal cortex and APA. In contrast, the mRNA levels of NR5A1 and the target 
gene CYP11B2 in adrenal cortex and APA were significantly higher than those in artery, non-CM 
and CM (Fig. 5a). 
 
Analysis of alternative noncoding exon 1 usage in human cardiovascular and adrenal tissues 
NGFIB ANE3 was preferentially used in human artery, adrenal cortex and APA. ANE1 
was used only at low levels in all tissues analyzed in this study. NGFIB employed ANE2 at 
distinct levels between cardiovascular and adrenal tissues: ANE2 was the dominant noncoding 
exon 1 used in cardiovascular tissues. CM tissue showed up-regulation of ANE4 and down-
regulation of ANE3 compared to cardiac muscle tissue without disease (Fig. 5b). 
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NURR1 ANE1a usage was high in artery compared to other tissues. NOR1 ANE1 usage 
was high in CM compared to other tissues. SF1 used ANEs differentially between cardiovascular 
and adrenal tissues (Fig. 5b). 
 
NGFIB and NURR1 differentially use ANEs between APA and artery 
NGFIB and NURR1 were regulated between APA and artery in a tissue-specific manner. 
The use of NGFIB ANE 4 in APA was twice that seen in artery (42.3% vs. 21.5%; P < 0.0001) 
(Fig. 6). NGFIB serves a protective function for atherosclerosis [21, 22] whereas the role of 
NURR1 in atherosclerosis remains unknown. Targeting ANE4-specifc transcripts may reduce 
NGFIB function specifically in APA without loss of its function in artery. Likewise, we could 
target either ANE 1a or 2 of NURR1 to decrease NURR1 activity only in APA, avoiding 
anticipated adverse effects on blood vessels (Fig. 6). Therapeutic strategies that target 
differentially-regulated ANEs of NGFIB and NURR1 may show clinical utility against primary 
aldosteronism.
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Discussion 
We report the genomic organization and structure of NR4A family and NR5A1 genes. We 
found a number of alternative promoters with noncoding first exons in the genes encoding the 
NR4A and NR5A families of nuclear receptors that regulate aldosterone synthase expression and 
thus aldosterone production. NGFIB and NURR1 showed significant differences in use of ANEs 
between APA and artery. 
Primary aldosteronism is the most frequent form of secondary hypertension, with prevalence 
rates of 5% to 13% [23]. APA and bilateral idiopathic hyperaldosteronism are the most common 
subtypes of primary aldosteronism. Patients with primary aldosteronism exhibit a higher rate of 
cardiovascular complications, target organ damage and metabolic syndrome. Unilateral 
adrenalectomy is a treatment option for patients with APA. Patients with bilateral idiopathic 
hyperaldosteronism are treated medically. In addition, APA patients may be treated medically. 
Mineralocorticoid receptor (MR) antagonists are currently the most commonly used treatment of 
primary aldosteronism. Although the use of MR antagonists shows clinical benefit in the 
treatment of primary aldosteronism, it also leads to severe side effects such as gynecomastia and 
endocrinal dysregulation. New therapeutic strategies that directly target the synthesis of 
aldosterone are preferred. 
The NGFIB response element (NBRE) within the CYP11B2 promoter has been shown to 
control transcription by its binding of members of the NR4A family (NGFIB, NURR1, NOR1) [8, 
9]. NGFIB and NURR1 are thought to up-regulate CYP11B2 expression in human adrenal cortex 
and APA [8, 10]. Thus, NR4A nuclear receptors are emerging as a candidate therapeutic target in 
primary aldosteronism. All these nuclear receptors are also expressed in atherosclerotic lesions 
[24], and appear to exert a direct influence on vascular remodeling, including cell viability and 
proliferation, inflammation [25]. NGFIB exerts a favorable effect on artery in terms of 
atherosclerosis [21, 22] whereas NOR1 appears atherogenic [26]. The pathophysiological role of 
NURR1 remains to be elucidated in atherogenic responses. Thus, NGFIB should be differentially 
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regulated between APA and artery to inhibit aldosterone synthase expression and prevent 
atherosclerosis: NGFIB should be down-regulated in APA, but not in artery. 
Although NGFIB and NURR1 transcripts from different tissues contain the same coding 
exons, they differ in the noncoding exon 1, which is transcribed from individual alternative 
promoters and subsequently spliced onto the common coding exons (Fig. 3a). The use of NGFIB 
ANE 4 in APA was twice that seen in artery (42.3% vs. 21.5%; P < 0.0001) (Fig. 5b). Targeting 
ANE4-specifc transcripts may lead to efficient reduction of NGFIB function specifically in APA, 
maintaining its function in artery. Since we observed a significant difference in use of ANEs (Fig. 
5b), NURR1 function could also be differentially controlled between APA and artery. Modulating 
alternative promoter usage of NGFIB and NURR1 may have clinical utility in the treatment of 
APA or cardiovascular disease. 
 A number of approaches could be employed to target NGFIB and NURR1. Oligo-DNA 
molecules may be introduced as „„decoy‟‟ cis-elements to block the activation of tissue specific 
promoters [27]. Alternatively, siRNA-directed transcriptional silencing may also be applicable if 
they were designed to target the tissue-specific ANE [28, 29]. Therefore, a difference in promoter 
usage among tissues is a potentially important target for effective treatments. We believe that our 
attempt to characterize this difference in aldosterone regulation between artery and primary 
aldosteronism will lead to a novel therapeutic option that efficiently suppresses aldosterone. 
In contrast to NR5A1 (SF1), NR4A family members are differentially expressed in a number 
of tissues of metabolic (heart, liver and adipose) and endocrine (hypothalamus, pituitary and 
adrenal glands) origin. A growing body of evidence is accumulating to demonstrate a critical role 
of NR4A receptors in regulating glucose and lipid homeostasis, adipogenesis, inflammation and 
vascular remodeling [25, 30]. Although NR4A function remains unclear in the heart, the acute 
induction of NR4A expression following β-adrenergic stimulation in the heart implicates the 
NR4A family as potential mediators of cardiac muscle metabolism associated with β-adrenergic 
signaling [31]. We observed changes in use of ANEs of NGFIB and NOR1 in CM compared to 
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cardiac muscle without disease (Fig. 5b). These observations may be associated with myocardial 
energetic impairment in CM. 
The tissue-restricted pattern of gene expression is predominantly determined by the action of 
alternative promoters. However, alternative noncoding exons can also modulate gene expression 
in a posttranscriptional manner [32]. Further experiments are required to elucidate the underlying 
mechanisms by which NR4A family and NR5A1 are differentially regulated between 
cardiovascular and adrenal tissues, for example by identifying cis-acting elements in the 
alternative promoter regions and determining the effect of alternative exons 1 on mRNA stability 
and protein translation. 
In summary, we reveal that nuclear receptors including NR4A family and NR5A1 
differentially used multiple promoters with ANEs in human cardiovascular and adrenal tissues. 
All these genes showed significant differences in use of ANEs between those tissues. These 
findings may provide opportunities for further investigation into the regulatory mechanisms of 
those genes.  
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Tables 
Table 1. Primers used in this study 
Real time RT-PCR 
Name Sequence (5'-3') 
Locus 
version 
*Position AT 
Product size 
(bp) 
NGFIB (NR4A1) F gcatggtgaaggaagttgtc 
NM_173157.1 1156-1268 60 113 
NGFIB (NR4A1) R cagggaagtgaggagattgg 
NURR1 (NR4A2) F agtctgatcagtgccctcgt 
NM_006186.2 1422-1503 60 82 
NURR1 (NR4A2) R tcgcctggaacctggaat 
NOR1 (NR4A3) F 
tggaatggtaaaagaagttgtc
c NM_006981.2 1794-1875 60 82 
NOR1 (NR4A3) R taatgggctctttggtttgg 
SF1 (NR5A1) F atggtcttcaaggagctgga 
NM_004959.3 1037-1131 60 95 
SF1 (NR5A1) R acctggcggtagatgtggt 
GAPDH F tcattgacctcaactacatggttt 
NM_002046.3 212-359 60 148 
GAPDH R ttgattttggagggatctcg 
COUP-TFI (NR2F1) 
F 
atcgtgctgttcacgtcaga 
NM_005654.4 2660-2769 60 110 
COUP-TFII 
(NR2F1) R 
gggtactggctcctcacgta 
COUP-TFII 
(NR2F2) F 
gcaagtggagaagctcaagg 
NM_021005.2 1472-1570 60 99 
COUP-TFII 
(NR2F2) R 
tcagagagaccacaggcatct 
NR2F6 F ctacacctgccggtccaac NM_005234.3 389-476 60 88 
20 
 
NR2F6 R ccggaagcacttcttgagac 
 
5'-rapid amplification of cDNA ends (5'-RACE) 
Name Sequence (5'-3') Locus version *Position AT  
NGFIB 268R atggtgggcttgatgaactc NM_173157.1 c249-268 60 1st round PCR 
NGFIB 206R actcggtgctggtgtcccatatt 
 
NM_006186.2 
c184-206 66 
2nd round PCR 
(nested PCR) 
NURR1 
338R 
catggcttcagccgagtta c320-338 60 
 
NR5A1 525R atctgtgccttcttctgctgtttca NM_004959.3 c501-525 66  
 
Quantitative multiplex RT-PCR 
Name Sequence (5'-3') 
Locus 
version 
*Position AT 
Product 
size 
(bp) 
 
NGFIB ANE1 
F 
aaaagcgggggtggagag 
NT_029419.
12 (genomic 
DNA) 
14574493- 
14574510 
60 
147,  267 
DBTSS 
NGFIB ANE2 
F 
tgtctgggacctttttccag 
14580953-
14580972 
155 
DBTSS 
NGFIB ANE3 
F 
cagggaccaggctgagac 
14588600-
14588617 
165 
5'-RACE, 
NCBI 
(canonical) 
NGFIB ANE4 
F 
attcctgccaccttgctg 
14591313-
14591330 
210 
5'-RACE, 
(novel) 
NGFIB 268R- 6-FAM- NT_029419. c14591503-   
21 
 
FAM atggtgggcttgatgaactc 12 (genome 
DNA) 
14591522 
NM_173157.
1 (mRNA) 
c249-268 
NURR1 
ANE1a F 
aactgcacttcggcagagtt 
NT_005403.
17 (genome 
DNA) 
c7398443-
7398462 
60 
183 
5'-RACE, 
NCBI 
(canonical) 
NURR1 
ANE1b F 
tcagtttatgcgttgcttgg 
c7397981-
7398000 
191 
DBTSS 
NURR1 ANE2 
F 
aacagggaaggcatggaag 
c7396803-
7396821 
229 
5'-RACE, 
(novel) 
NURR1 
12.5kb F 
ggaagggaggagggagac
t 
c7408567-
7408585 
(UD) 
DBTSS  
(12.5 kb 
upstream of 
coding region) 
NURR1 4kb F gctgcagattagggttgagc 
c7400200- 
7400219 
(UD) 
DBTSS  
(4 kb upstream 
of coding 
region) 
NURR1 1.8kb 
F 
ggggttcgagtctcctttct 
c7397725-
7397744 
(UD) 
DBTSS  
(1.8 kb 
upstream of 
coding region 
NURR1 338R-
VIC 
VIC-
catggcttcagccgagtta 
NT_005403.
17 (genome 
7396114-
7396118, 
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DNA) 7396598-
7396611 
NM_006186.
2 (mRNA) 
c320-338 
NOR1 ANE1 
F 
accgccacagcactcaaag 
NM_006981.
2 
(mRNA) 
537-555 
60 
289 
NCBI 
(canonical) 
NOR1 ANE2 
F 
aatcagatttggaaatgtgga
tatg 
NM_173200.
1 
(mRNA) 
56-80 118 
NCBI 
(canonical) 
NOR1 825R-
NED 
NED-
gttcatgatctccgtggtgtat
t 
NM_006981.
2 (mRNA) 
c803-825 
 
 
NM_173200.
1 
(mRNA) 
c151-173 
NR5A1 
ANE1a  F 
gtggtgtgagggggtttc 
NT_008470.
19 (genome 
DNA) 
c56434167-
56434184 
60 
254 
5'-RACE, 
NCBI 
(canonical) 
NR5A1 
ANE1b F 
gggtctcccagactcacc 
c56433911-
56433928 
289 
DBTSS 
NR5A1 17kb F gctctctgatgaggcaagaa 
c56447311-
56447330 
(UD) 
DBTSS  
(17kb 
upstream of 
coding region 
NR5A1 2kb F aaacgaatcccaatcgaag 
c56430507- (UD) DBTSS 
23 
 
56430525 (2kb upstream 
of coding 
region 
NR5A1 301R-
PET 
PET-
cttgaagaagcccttgcag 
NT_008470.
19 (genome 
DNA) 
56430105-
56430111,  
56430020-
56430031 
 
 
NM_004959.
3 (mRNA) 
c283-301 
F, forward primer; R, reverse primer; AT, annealing temperature; c, complementary; UD, 
undetectable; DBTSS, DataBase of Transcriptional Start Sites (http://dbtss.hgc.jp/). 
*Amplicon and primer positions refer to numbering of the original sequence submission from 
National Center for Biotechnology Information (NCBI). 
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Figure legends 
Figure 1 
Responses of the CYP11B2 gene to angiotensin II (Ang. II), KCl, and cAMP. (a) NR4A family. 
(b) NR2F family. Values are means ± SD. *p<0.05, **p<0.01, ***p<0.001, vs basal, two tailed 
Student‟s t-test. 
 
Figure 2 
Identification of novel NGFIB and NURR1 noncoding exons 1 in H295R cells. (a) NGFIB ANE4. 
2 transcription start sites were identified: the distal site was cloned in H295R cells whereas the 
proximal site in artery. Nucleotide numbers are relative to the distal transcription start site. The 
translation start site, “ATG” of NGFIB is in uppercase. (b) NURR1 ANE2. 3 transcription start 
sites were identified. Nucleotide numbers are relative to the most distal transcription start site. 
Bold and capital letters indicate transcription start sites identified by means of 5'-RACE.  
 
Figure 3 
Schematic representation of alternative promoter regions and splicing events. Multiple alternative 
noncoding exons 1 and splicing events were observed in NR4A family (NGFIB, NURR1, NOR1) 
and NR5A1 (SF1). (a) NGFIB, (b) NURR1, (c) NOR1, (d) NR5A1. 
 
Figure 4 
Alternative noncoding exon 1 (ANE) usage (%) of NR4A family (NGFIB, NURR1, NOR1) and 
NR5A1 (SF1) in H295R cells. Values are means ± SD. *p<0.001, vs basal, two tailed Student‟s t-
test. 
 
Figure 5 
25 
 
Gene expression levels and promoter usage of NR4A family (NGFIB, NURR1, NOR1), NR5A1 
and CYP11B2 in human cardiovascular and adrenal tissues. (a) mRNA expression levels 
(mmoles/GAPDH moles). (b) Promoter usage (%).Values are means ± SEM. Statistically 
significant differences determined by two-tailed Student‟s or Welch‟s t-test. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. CM, cardiomyopathy; APA, aldosterone-producing adenoma. 
 
Figure 6 
Summary of preferential regulation of the NGFIB and NURR1 genes. Values are means ± SEM. 
Statistically significant differences determined by two-tailed Student‟s or Welch‟s t-test. AP; 
alternative promoter, ANE; alternative noncoding exon 1; APA, aldosterone-producing adenoma.
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-60 ctttgtggca cctaggtcga gatggtactc aggccagggg tcaggattcc tgggtgctct
+1 Ggtcccggtg cctctgtctc atctttaggc tgggattcct gccaccttgc tgctctgggg
+61 cccaaatact ttgagacaag gctataggct tgtcccactg actctccttt ccctccCtgg
+121 ggtctcctct ctctccagag ATGccctgta tccaagccca atatgggaca ccagcaccga
Figure 2a
-60 tcttcatact caggtcctga attaacctaa gatggaaatg acctctccac ctacactgta 
+1 Gcaaaggggc cagttcatta catcataaat gttaaatgag ttcatggact agctttcctc 
+61 ttgcaggatc ttctctctgc aaggatttac acagtgcaat gggtggtatt ttctGttgtt 
+121 tcaagtcatt tcttttatac attcatttta agtgctatgt ttggtaaagg cttcccactc 
+181 atttccaatg agacaaacaG ggaaggcatg gaagggcctg cctggtgagt ctacatatgc 
+241 ccagctgaat ctctgtcggg aagaaaccct gaagcttcct gtgtctgtat ttcagggagg
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